NOVELIX (NOVELIX) | Stock Overview & Key Data
NOVELIX Performance Comparison
Stock Range
Today's Range
Low: ₹39.90
High: ₹42.00
on August 11, 2025
52 Week Range
Low: ₹26.61
High: ₹52.79
on April 7, 2025
All-Time High: ₹52.79 on July 15, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR532.4M
EPS
0.08
P/E Ratio (TTM)
514.50
Forward P/E
N/A
P/B Ratio
2.34
PEG Ratio
N/A
Div. Yield
N/A
ROE
0.68%
Beta
0.317
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
2.77%
Operating Margin
1.01%
Profit Margin
0.28%
Returns and Earnings
Return on Assets (TTM)
0.45%
Return on Equity (TTM)
0.68%
EBITDA
INR1.5M
Net Income (TTM)
INR845.0K
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR30.89
Quarterly Revenue Growth (YoY)
2,129.80%
Quarterly Earnings Growth (YoY)
-34.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| NOVELIX NOVELIX | 532.40M Small-cap | 2.09% | -5.15% | 50.32% | 57.84% | 57.84% | 57.84% | 57.84% | 57.84% |
| Entero Healthcare ENTERO | 51.95B Mid-cap | -1.13% | 5.00% | -4.26% | -7.68% | -10.23% | 4.72% | 12.11% | 12.11% |
| Amwill Health Care AMWILL | 1.19B Small-cap | 0.12% | -11.19% | -28.20% | -36.19% | -36.19% | -39.53% | -39.53% | -39.53% |
| Royal Sense ROYAL | 1.10B Small-cap | -0.97% | -14.37% | -5.51% | -22.64% | -33.01% | 41.38% | 83.91% | 83.91% |
| Trimurthi TRIMURTHI | 264.77M Small-cap | 2.09% | -5.15% | 50.32% | 65.68% | 73.91% | 111.27% | 425.00% | 1,128.07% |
| Zenlabs Ethica ZENLABS | 214.64M Small-cap | -4.05% | -4.79% | 0.60% | -8.96% | -20.06% | -19.26% | -27.87% | 35.55% |
Ownership & Short Interest
Insider Ownership
63.61%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
6K
Average 90-Day Volume
24K
NOVELIX Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in NOVELIX would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NOVELIX's 52-week high and low?
- In the last 52 weeks, NOVELIX reached a high of ₹52.79 (on N/A) and a low of ₹26.61 (on April 7, 2025).
- What is the market cap and P/E ratio for NOVELIX?
- Curious about NOVELIX's size and valuation? Its market capitalization stands at 532.40M. When it comes to valuation, the P/E ratio (trailing twelve months) is 514.50, and the forward P/E (looking ahead) is N/A.
- Does NOVELIX pay dividends? If so, what's the yield?
- As for dividends, NOVELIX isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are NOVELIX's main competitors or similar companies to consider before investing?
When looking at NOVELIX, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Entero Healthcare
ENTERO51.95B Healthcare Medical Distribution 4.72% 12.11% Amwill Health Care
AMWILL1.19B Healthcare Medical Distribution -39.53% -39.53% Royal Sense
ROYAL1.10B Healthcare Medical Distribution 41.38% 83.91% Trimurthi
TRIMURTHI264.77M Healthcare Medical Distribution 111.27% 425.00% Zenlabs Ethica
ZENLABS214.64M Healthcare Medical Distribution -19.26% -27.87% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for NOVELIX PHARMACEUTICALS LIMITE? (e.g., ROE, Debt/Equity)
- To get a sense of NOVELIX's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.68%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 2.77%.
- What is the recent revenue and earnings growth for NOVELIX?
- Looking at NOVELIX's growth, its revenue over the trailing twelve months (TTM) was INR307M. Compared to the same quarter last year (YoY), quarterly revenue grew by 2,129.80%, and quarterly earnings saw a YoY growth of -34.00%.
- How much of NOVELIX stock is held by insiders and institutions?
- Wondering who owns NOVELIX stock? Company insiders (like executives and directors) hold about 63.61% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.